PeptiDream Announces the Appointment of Dr. Keiichi Masuya as Chief
Operating Officer (COO) at PeptiDream Inc.
TOKYO -- July 16, 2014
PeptiDream Inc., a public Tokyo-based biopharmaceutical company (PeptiDream)
(TOKYO:4587) announced today, the appointment of Dr. Keiichi Masuya as Chief
Operating Officer (COO).
Dr. Masuya has had a distinguished scientific career, most recently serving as
“Novartis Leading Scientist” at Novartis in Basel, Switzerland. Dr. Masuya has
worked for Novartis for the past 14 years, 10 of those years in Basel,
Switzerland and 4 years at the Novartis Institutes for Biomedical Research in
Tsukuba, Japan. Dr. Masuya led the project team through the discovery and
development of Zykadia (ceritnib, LDK378) for the treatment of non-small cell
lung cancer (NSCLC), which received FDA Breakthrough Therapy designation in
2013 and was approved in early 2014. He also led the project team in the
discovery and development of CGM097, for the treatment of advanced solid
tumors, which is currently in Phase I testing. Dr. Masuya is a leading expert
in the field of PPI inhibitors (protein-protein interaction inhibitors), and
has an exceptional track record of discovering and bringing lead candidates
into clinical development.
At PeptiDream, in his role as COO, Dr. Masuya will head PeptiDream’s in house
discovery and development programs, and in addition, manage PeptiDream’s Japan
discovery collaborations. Dr. Masuya’s extensive experience in drug
development with significantly elevate the ability of PeptiDream to bring its
in house discovered peptides into the clinic at an accelerated pace and with
greater efficiency. Dr. Masuya received his Ph.D. from the Tokyo Institute of
Technology in 1998. Dr. Masuya has received numerous awards, including the
VIVA award as Novartis’s leading scientist, and is the author of numerous
scientific papers and inventor of more than 30 patents.
[Comments from Kiichi Kubota, CEO of PeptiDream Inc]
“We are very excited to have been able to successfully recruit Dr. Masuya to
PeptiDream and believe his exceptional drug discovery track record and
experience will prove invaluable to PeptiDream as we look to accelerate the
development of our own in house discovered peptide drug candidates and rapidly
advance them into the clinic.”
[Comments from Dr. Keiichi Masuya]
“PeptiDream has established itself as the world leader in the discovery of
peptide-based therapeutics, an accomplishment well-recognized among global
pharmaceutical companies, and exemplified in PeptiDream’s impressive list of
global discovery partners. I greatly look forward to joining PeptiDream and
use my experience to accelerate discovery and develop efforts at PeptiDream
and drive internal programs into the clinic”.
Patrick C Reid, +81-3-3485-7707 (Tokyo)
Press spacebar to pause and continue. Press esc to stop.